Abstract
Pancreatic neuroendocrine tumours (PanNETs) have intra-tumour heterogeneity, notably regarding the Ki-67 index, which is a major prognostic factor. The temporal evolution of PanNET biology is poorly known. We aimed to study the prognostic impact of the temporal evolution of Ki-67 and other molecular markers (MEN1, ATRX/DAXX, PDX1/ARX) in PanNETs. We retrospectively studied 109 patients with sporadic PanNETs and serial tumour samples (n=286), on which we measured the Ki-67 index and the expression of the other markers. Variables associated with shorter overall survival [OS] and Ki-67 increase over time were explored using multivariable analyses. The median time between the initial and last samples was 49.4 months, with a median variation in Ki-67 of +4% (interquartile range [IQR], -1 to +15%; p<0.001) and +0.5%/year (IQR -0.2 to +3.3%). Tumour grade increased in 36% of cases. At multivariable analysis, increase of Ki-67 ≥ 2%/year was associated with shorter OS (HR 1.96, 95% CI [1.02-3.73], p=0.041). This variation was more common in patients who received alkylating agents (OR 4.47, 95%CI [1.48-15.38, p=0.011) and was less common in those who achieved tumour control with somatostatin analogues (OR 0.27, 95%CI [0.08-0.82], p=0.027). MEN1 and ATRX/DAXX expressions were stable over time while the proportion of alpha-like signature (PDX1-/ARX+) decreased (p=0.016); none was associated with Ki-67 nor influenced prognosis. Overall, an increase of PanNET grade and Ki-67 index is frequent over time, indicates poorer prognosis, and is promoted by alkylating agents. Rebiopsy during PanNET evolution seems relevant to adjust prognosis evaluation and therapeutic strategy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call